Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024

LONDON, January 29, 2014 /PRNewswire/ --

Biotechnology for bone disorders - new study showing you trends, R&D progress, and predicted revenues

What's the future of orthobiologics and osteobiologics? Visiongain's updated report gives you predictions for those medical devices and pharmaceuticals. There you explore sales results, technologies, needs, R&D, opportunities, and revenue forecasts.

So see what's possible for those bone-repairing agents and related biotechnologies for bone diseases. You gain data and financial analysis for that industry. There find technological progress and commercial prospects for technology and medicines. Discover potential gains.

Read on to explore those treatments and see what their future market could be worth.

Forecasts and other analyses of technology for healing damaged bones

Orthobiologics constitute products using biology or biochemistry to treat musculoskeletal disorders. Sales of those drugs and other reconstructive therapies expand.

Our report covers two main segments: bone graft substitutes and biological treatments for osteoporosis. It then analyses components of those submarkets.

That new study gives you sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies in bone repair. There find potentials, hearing how you can gain.

Besides forecasting revenues to 2024, that work shows you historical results, growth rates, and market shares. There you explore technologies, applications, and developments (R&D). You also gain 64 tables, 60 charts, and two interviews with other authorities.

Knowledge to benefit your work and save time, helping your influence

Ever had trouble finding data you need? See in our report how you could help your business research, analyses, and decisions on treatments for debilitating bone conditions. Save time too. Also benefit your authority through better understanding the present and future.

So the following sections explain what you get in our new investigation.

Forecasting of that world market and its main segments - you explore possibilities

What're the secrets of that industry's progress? Where lies potential in treating bone disorders? Discover in our work overall world revenue to 2024 for orthobiologics and biologics for osteoporosis.

Also in that report you find individual revenue predictions to 2024 for six therapeutic submarkets at world level for orthobiologics:
• Machined bone allografts
• Demineralised bone matrices
• Recombinant growth factors
• Bone substitutes
• Stem-cell therapies
• Allograft implants.

There you assess outlooks for sales growth, seeing where you can gain.

So you explore competition and rising sales for products in orthopaedics (orthopedics), and related technology for rebuilding bones, including biological drugs (biologics). You get feel for that sector and its potential.

Discover the lucrative, expanding possibilities there. You also assess top products' futures.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

Predictions of leading osteopathic agents' revenues

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for products, marketed and expected:
• INFUSE
• Prolia
• Forteo
• Preotact
• Romosozumab
• Biosimilars (follow-on biologics) for osteoporosis, grouped analysis.

There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and sales potentials. See where you could profit.

Our work also divides its overall predictions into geographical regions.

Healthcare in leading national markets - what outlooks for those medical sales?

In developed and developing countries, opportunities for providers of bone treatments will increase from 2014 to 2024. See where and how, finding sales potentials for therapeutics.

Separately for orthobiologics and biologics for osteoporosis, our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential revenue growth. Our work explains. You assess needs and demands for that specialist medicine.

Explore, too, how that biomedical and biopharma technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing trends and needs.

Events and forces for developing, producing, marketing, and selling those bone medicines

Our report shows you issues and events affecting that biomedical and pharmaceutical sector from 2014, including these:
• Bisphosphonates to monoclonal antibodies (mAbs) - therapies to improve bone density
• Bone graft substitutes, orthopaedic devices and biologics suiting minimally-invasive surgery, inc. orthopaedic biomaterials
• Stem cell therapies and Map3 and i-Factor bone grafts
• Expanding markets for bone therapy, including effect of demographics on demand
• Research and development (R&D) pipelines, inc. donor cell therapy, tibia fusing, spinal fusion, mimetic peptides, romosozumab, and blosozumab.

So you explore political, economic, social, and technological questions for treating bone disorders, investigating outlooks for commerce. Discover what the future holds.

Examine, then, what stimulates and restrains players in that industry, and affects its results.

Companies and 2018 market value - find prospects for success

What happens next? From 2014 novel treatments and regulations there encourage investments, medical advances, and higher revenues.

So our study predicts the world market for orthobiologics will reach $4,561m in 2018. There big pharma and specialty companies can gain, expanding business. Explore how and where.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

And there you examine activities of many organisations, including these participants:
• Eli Lilly
• Amgen
• Medtronic
• Johnson & Johnson (DePuy Synthes)
• NuVasive.

Also these firms, among others:
• Baxter International
• Biomet
• Zimmer
• RTI Biologics.

R&D for treating bone damage holds advantages, and from 2014 there will arise many opportunities. From this decade, patients, payers, and producing companies will benefit.

And you discover how those market segments can perform, staying ahead in knowledge.

Ways Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024  helps

In particular, that new investigation gives you these advantages:
• Revenues there to 2024 at world level, for 7 submarkets, and 5 products - examine outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - assess developed and developing countries for potential revenues
• Prospects for established competitors, emerging companies, and new entrants - explore portfolios, results, strategies, successes, and developmental activities.

Information found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore the business possibilities.

With our data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find how you could save time and effort with our study, helping your planning, decisions, and authority.

Predictions for bone-healing technologies and products - gain now by trying our report

Our new report is for everyone investigating bone therapy - drugs and other solutions. There find commercial projections to help your work. So avoid missing out - please order now.

To request an exec summary of this report please email Sara Peerun at            sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1188/Ortho-and-Osteobiologics-World-Industry-and-Market-Analysis-2014-2024

Companies Listed in this Report:

AAP Implante
Allosource
Alphatec
Amgen
Angel Biotechnology
ApaTech
Arthrocare
Atheriocyte Medical Systems Inc
Athersys
Azelon Pharmaceuticals
Bacterin
Baxter
Berkeley Advanced Biomaterials Inc
Biocomposites
Biocoral
Biological Therapies
Biomatlante
Biomet
BioMimetic Therapeutics
BioSET
BioTissue
BonAlive Biomaterials
Bone Biologics
Bone Solutions
Bone Therapeutics
BoneSupport
Brazilian Unified Health System (SUS)
Cardium Therapeutics
Celltech
Centre for Devices and Radiological Health (CDRH)
Ceramisys
Cerapedics
co.don
Collagen Matrix
Curasan
Cytomedix
Daiichi Sankyo
DePuy Synthes
Eli Lilly
ETEX Corporation
European Medicines Agency (EMA)
European Union (EU)
Exactech
Fitch Ratings
Food and Drug Administration (FDA)
Forest Laboratories
Geistlich Biomaterials
German Institute for Quality and Efficiency in Healthcare (IQWiG)
GlaxoSmithKline (GSK)
Globus Medical
Graftys
Histogenics Corporation
Integra LifeSciences
ISTO Technologies
Johnson & Johnson
Kasios
Kensey Nash
Kinetic Concepts
Kuros Biosurgery
Lindare Medical
Medtronic
Merck & Co
Mesoblast
MicroPort Medical
MiMedx Group
Monet Medical
Musculoskeletal Transplant Foundation
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
NovaBone Products LLC
Novartis
NPS Pharmaceuticals
NuVasive
Nycomed
Olympus Biotech
Orteq Bioengineering
Orthofix
Orthovita
Osiris Therapeutics
OsteoGeneX
Osteotech
Parcell Laboratories
Pharma and Medical Devices Agency (PMDA)
Pioneer Surgical Technologies
PolyNovo Biomaterials
Progenteq
Radius Health
Roche
Royal DSM
RTI Biologics
Scorpion Medical
Spinal Restoration
SpineSmith Partners LP
State Food and Drug Administration (SFDA, China)
Stryker
Takeda
Teknimed
Teva Pharmaceutical Industries
Tigenix
Tissue Banks International
Tissue Genesis
TissueGene
Tornier
UCB
Winthrop University Hospital
World Health Organization (WHO)
Wright Medical
Yale University
Zimmer
Zosano Pharma

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com